Oragenics (NYSEAMERICAN:OGEN) Trading 2.6% Higher – Here’s Why

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s share price traded up 2.6% during trading on Friday . The company traded as high as $0.5899 and last traded at $0.5871. Approximately 39,441 shares changed hands during trading, a decline of 20% from the average daily volume of 49,473 shares. The stock had previously closed at $0.5725.

Oragenics Stock Up 2.6%

The stock has a 50-day moving average of $0.61 and a 200 day moving average of $0.72. The stock has a market cap of $2.65 million, a PE ratio of -0.03 and a beta of 1.27.

Oragenics (NYSEAMERICAN:OGEN) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

Hedge funds and other institutional investors have recently made changes to their positions in the business. DRW Securities LLC raised its holdings in shares of Oragenics by 82.4% during the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after purchasing an additional 50,900 shares during the last quarter. Bank of America Corp DE boosted its holdings in Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the last quarter. XTX Topco Ltd purchased a new stake in Oragenics in the fourth quarter valued at $26,000. Finally, Sabby Management LLC purchased a new stake in Oragenics in the third quarter valued at $77,000. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.